WO2006126714A1 - ペルオキシソーム増殖剤活性化受容体の活性化剤 - Google Patents
ペルオキシソーム増殖剤活性化受容体の活性化剤 Download PDFInfo
- Publication number
- WO2006126714A1 WO2006126714A1 PCT/JP2006/310822 JP2006310822W WO2006126714A1 WO 2006126714 A1 WO2006126714 A1 WO 2006126714A1 JP 2006310822 W JP2006310822 W JP 2006310822W WO 2006126714 A1 WO2006126714 A1 WO 2006126714A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbon atoms
- group
- atom
- compound
- salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Definitions
- the present invention relates to an activator of peroxisome proliferator activated receptor (PPAR).
- PPAR peroxisome proliferator activated receptor
- P PAR re Peroxisome proliferato ractivated receptor: P PAR re (Makore! (Proc. C. Tl. A cd. S ci. USA, 9 1, p 7 3 3 5-7 3 5 9, 1 9 9 4 (Non-patent Document 1))
- KR P-297 (Merck-Kyorin) and non-TZD derivatives] iuraglitazar (BMS / Merck), Tesaglitazar (Astra Zeneca), etc.
- PPAR ⁇ as the main action and have been developed as anti-diabetic drugs. It has been reported that the activity of P PAR c is not necessarily strong.
- PP AR ⁇ selective agonist as PP AR ⁇ selective agonist,
- GW— 5 0 1 5 1 6 (G S K) is known, and it has been reported that development is in progress as an agent for improving lipid metabolism.
- Patent Document 1 WO 0 1/6 0 3 (Patent Document 1)
- the following formula is a fibrate derivative in which a phenyl-lazine residue is introduced into the methyl group of the thiazole ring of GW-5 0 1 5 1 6 ,
- An object of the present invention is to provide a compound represented by the following general formulas (I) and ( ⁇ ), which has an activating effect on a peroxyseme proliferator-activated receptor. That is, the present invention provides the following general formula (I)
- A represents CH or a nitrogen atom
- B represents an oxygen atom or C (R 8 ) (R 9 ), wherein R 8 and R 9 may be the same or different and each represents a hydrogen atom or an alkyl group having 1 to 8 carbon atoms,
- X and Y differently represent an oxygen atom, a sulfur atom, a nitrogen atom or CR 12 where R 12 represents a hydrogen atom or an alkyl group having 1 to 8 carbon atoms,
- Z 1 represents a bond, an oxygen atom, a sulfur atom or C (R 13 ) (R 14 ), wherein R 13 and R 14 may be the same or different, and may be a hydrogen atom or an alkyl having 1 to 8 carbon atoms. Represents the group
- RR 2 and R 3 may be the same or different and are a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkenyl group having 2 to 8 carbon atoms, an alkynyl group having 2 to 8 carbon atoms, or 1 to 8 carbon atoms.
- R 4 and R 5 may be the same or different and each represents a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, or an alkyl group having 1 to 8 carbon atoms substituted with a halogen atom;
- R 6 and R 7 may be the same or different and substituted with a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkenyl group having 2 to 8 carbon atoms, an alkynyl group having 2 to 8 carbon atoms, or a halogen atom. Represents an alkyl group having 1 to 8 carbon atoms,
- ⁇ represents an integer of 1 to 5.
- Z 2 represents an oxygen atom or a sulfur atom
- R 21 , R 22 and R 23 may be the same or different from each other; a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkenyl group having 2 to 8 carbon atoms, an alkynyl group having 2 to 8 carbon atoms, and a carbon number of 1 to 8 alkoxy groups, halogen atoms, alkyl groups having 1 to 8 carbon atoms substituted with halogen atoms, alkoxy groups having 1 to 8 carbon atoms substituted with halogen atoms, hydroxyl groups, nitro groups, 2 to 8 carbon atoms
- An acyl group of 6 to 10 carbon atoms or a 5- or 6-membered heterocyclic group, and R 24 and R 25 may be the same or different from each other, a hydrogen atom, and a carbon number of 1 to 8 O represents an alkyl group or a C1-C8 alkyl group substituted with a halogen atom o)
- the present invention relates to a peroxisome proliferator-activated receptor activator comprising as an active ingredient the compounds represented by the above general formulas (I) and (II) or salts thereof.
- Examples of the alkyl group having 1 to 8 carbon atoms of 4 include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an i-butyl group, a t-butyl group, a pentyl group, and a hexyl group.
- Examples of the alkenyl group having 2 to 8 carbon atoms of R 1 , R 2 , R 3 , R 6 and R 7 include a vinyl group and an aryl group.
- Examples of the alkyl group having 2 to 8 carbon atoms of R 1 , R 2 , R 3 , R 6, and R 7 include an open pargyl group.
- alkoxy group having 1 to 8 carbon atoms of R 1 , R 2 and R 3 examples include methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group, i-ptoxy group, t-butoxy group, pentyloxy group Group or hexyloxy group.
- halogen atoms examples include a fluorine atom, a chlorine atom, or a fluorine atom.
- R 1 R 2 , R 3 , R 4 , R 5 , R 6, and R 7 substituted with halogen atoms include 1 to 8 carbon atoms, such as 1 to 3 fluorine atoms, chlorine atoms, or fluorine atoms. Examples thereof include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group or a t-butyl group substituted with a halogen atom such as an atom, preferably a trifluoromethylol group, a chloromethyl group, a 2-chloroethyl group, and a 2-chloroethyl group. Group, 2-bromoethynole group or 2-monofluoroethyl group.
- alkoxy group having 1 to 8 carbon atoms substituted by the halogen atom of R 1 , R 2 or R 3 a group substituted by a halogen atom such as 1 to 3 fluorine atom, chlorine atom or bromine atom is used.
- Toxyl group, ethoxy group, propoxy group, isopropyloxy group, butyloxy group or tert-butyloxy group, etc. are preferable, preferably trifluoromethenoreoxy group, quino, oral romethinoreoxy group, 2-chloroethenoreoxy group, 2-butyl group
- Examples include lomoethyloxy group and 2-fluoroethyloxy group.
- the acyl group having 2 to 8 carbon atoms of R 1 R 2 and R 3 include a acetyl group or a propionyl group.
- Examples of the aryl group having 6 to 10 carbon atoms of R 1 R 2 and R 3 include a phenyl group.
- Examples of the 5- or 6-membered heterocyclic group of R 1 R 2 and R 3 include a pyridyl group.
- Examples of the group, the aryl group having 6 to 10 carbon atoms, or the 5- or 6-membered heterocyclic group include those exemplified for RR 2 and R 3 in the general formula (I).
- R 24 and R 25 alkyl groups having 1 to 8 carbon atoms or alkyl groups having 1 to 8 carbon atoms substituted by a halogen atom include those in the above general formula (I).
- the same as those exemplified for R 4 and R 5 in FIG. R 1 , R 2 , and R 3 in the general formula (I) and R 2 1 , R 2 2, and R 2 3 in the general formula (II) are substituted with benzene substituted by R 1 or the like.
- R 1 to 3 identical or different ones may be present.
- the compound of the present invention the following compounds are preferred.
- the compound of the present invention is preferably a compound represented by the above general formula (I) wherein A is CH or a salt thereof.
- the compound of the present invention is preferably a compound of the above general formula (I), wherein B is an oxygen atom, or a salt thereof or a salt thereof.
- the compound of the present invention is preferably the compound represented by the above general formula (I), wherein W 1 is a bond, or the compound of the above (1) or (2) or a salt thereof.
- X is a sulfur atom and Y is a nitrogen atom, and the compound of the above general formula (I), or the above (1) to (4) or a salt thereof is preferable.
- Z 1 is preferably an oxygen atom or a sulfur atom, or a compound or a salt thereof described in the above general formula (I), or (1) to (6) above.
- R 1 R 2 and R 3 may be the same or different, a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkenyl group having 2 to 8 carbon atoms, or 1 to
- R 4 and R 5 which may be the same or different, are a hydrogen atom or a methyl group, or a compound described in the above general formula (I) or (1) to (8) Or a salt thereof.
- R 6 and R 7 may be the same or different, and may be a hydrogen atom or an alkyl group having 1 to 8 carbon atoms, or the above general formula (I) or (1) To (9) The compound or a salt thereof is preferred.
- n is an integer of 2 to 4, and the compounds described in the above general formula (I) or (1) to (10) or salts thereof are preferable.
- the compound of the present invention is preferably a compound represented by the above general formula (II) or a salt thereof wherein W 2 is a bond.
- R 21 , R 22 and R 23 may be the same or different, and may be a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkenyl group having 2 to 8 carbon atoms, or 1 carbon atom.
- the above general formula (I 1) which is an alkoxy group having ⁇ 8, a halogen atom, an alkyl group having 1 to 8 carbon atoms substituted with a halogen atom, or an alkoxy group having 1 to 8 carbon atoms substituted with a halogen atom.
- the compound described in (13) above or a salt thereof is preferred. .
- R 24 and R 25 may be the same or different and the hydrogen atom or the methyl group is the above general formula (1 1) or the above (1 3) or (14) Or a salt thereof.
- the compound of the present invention represented by the above general formula (I) or (II) may be a pharmacologically acceptable salt such as sodium, potassium, lithium and the like. Is mentioned.
- the compound of the present invention may contain optical isomers such as optically active substances and racemates, and geometric isomers of cis and trans, etc., all of which are included in the present invention.
- a synthesis scheme of the compound of the present invention represented by the general formula (I) is shown below. In the case of an oxygen atom, a compound represented by the general formula (I)
- the compound represented by the general formula (c) is represented by the compound represented by the general formula (a) and the general formula (b). It can be obtained by reacting the compound with a solvent such as THF that does not participate in the reaction.
- the compound represented by the general formula (c) and the compound represented by the general formula (d) are mixed with the presence of potassium carbonate in a solvent that does not participate in the reaction such as acetone or 2-butanone.
- the compound represented by the general formula (e) can be obtained by reaction.
- the compound of the present invention represented by the general formula (f) can be obtained by subjecting the compound represented by the general formula (e) to a hydrolysis reaction using lithium hydroxide or the like.
- the compound represented by the general formula (a) as the starting material can be obtained, for example, by the following method.
- R represents a lower alkyl group such as an ethyl group
- B n represents a benzyl group
- THP represents a tetrahydropyrael group
- J represents an integer of 1 to 4
- Q 3 represents a chlorine atom.
- A, X, Y, R 1 and R 3 are the same as described above.
- the compound represented by the general formula (3) is a benzoyl oxalate ester represented by the general formula (1).
- the derivative and the compound represented by the general formula (b) are reacted in a solvent that does not participate in the reaction such as THF in the presence of a base such as sodium hydride, and then decarburized with monoacetic acid hydrochloride. It can be obtained by acid, debenzylation, and chlorine substitution of THP.
- the bur compound represented by the general formula (6) consists of an aldehyde compound represented by the general formula (5) and an acetophenone compound represented by the general formula (4) in the presence of a base. It can be obtained by a condensation reaction.
- the phenol compound represented by the general formula (7) can be obtained by subjecting the bur compound represented by the general formula (6) to the reductive reaction and debenzylation reaction of the olefin moiety.
- the compound represented by the general formula (8) can be obtained by acting monoacetic acid hydrochloride on the compound of the general formula (7) thus obtained.
- the compound of the present invention represented by the above general formula (I) or general formula (II) can also be produced by referring to the above-mentioned synthesis method and the examples described below, as well as the above-mentioned patent documents and known documents. . Examples of the compounds of the present invention thus obtained are shown in the table c
- the PPAR activation action of the compound of the present invention was measured as follows.
- Receptor expression plasmid (p SG 5— GAL 4—h PPAR aoryor ⁇ (L BD), luciferase expression plasmid (p UC 8 -MH 1 00 X 4— TK—L uc) ) And] 3-Galactosidase expression plasmid (p CMX-] 3-GAL) (K 1 iewer, S. A. et. A 1., (1 9 9 2) Nature, 3 5 8: 7 7 The gene was introduced using lipofection reagent D MR IE-C or Lipofectamine, 2000 (Invitrogen), and then cultured for 42 hours in the presence of the test compound.
- Solubilized cells were used to measure luciferase activity and —GA L activity.Luciferase activity was corrected by one GAL activity, and P PAR ⁇ was GW— 5 9 0 7 3 5 (PPAR ⁇ selective agonist) EC 5 was calculated by calculating the relative ligand activity with PAR ⁇ y as the rosiglitazone and P PAR S as the luciferase activity value of cells treated with GW_ 50 15 5 16 as 100%.
- Fruit Example 1 7) As is clear from Table 17, the compound of the present invention showed an excellent PPAR activation action.
- the compounds represented by the general formulas (I) and (II) of the present invention were excellent PP Since it has AR activation action, hypoglycemic agent, obesity, syndrome X, hypercholesterolemia, metabolic disorders such as hyperlipoproteinemia, hyperlipidemia, arteriosclerosis, circulatory system disease, It is expected as a prophylactic or therapeutic agent for bulimia, ischemic disease, lung cancer, breast cancer, colon cancer, colon cancer, ovarian cancer, etc., Alzheimer's disease, inflammatory disease, etc.
- the compound of the present invention is expected.
- a granule, a tablet, granule, or the like can be administered by a conventional method in the technical field of preparation.
- Scattered It can be manufactured into dosage forms such as pills, capsules, suspensions, injections, and suppositories.
- dosage forms such as pills, capsules, suspensions, injections, and suppositories.
- usual excipients, disintegrants, binders, lubricants, dyes, diluents, etc. are used.
- lactose, D-mannitol, crystalline cellulose, glucose, etc. are used as excipients
- starch, carboxymethyl cellulose calcium (CMC—Ca), etc. are used as lubricants as disintegrants.
- examples include magnesium stearate_ and tanolec
- examples of binders include hydroxyprovir cellulose (HP C), gelatin, and polyvinylpyrrolidone (PVP).
- Example Example 1 In adults, the dosage of the compound of the present invention, which is an active ingredient in injections, should be increased or decreased depending on the age, symptoms, etc. Can do. Next, the present invention will be described in more detail with reference to examples, but the present invention is not limited thereto.
- Example Example 1 In adults, the dosage of the compound of the present invention, which is an active ingredient in injections, should be increased or decreased depending on the age, symptoms, etc. Can do.
- the title compound was obtained as a colorless oil in the same manner as (2) of Example 1 using 11 (41-isopropylphenyl) piperazine.
- the title compound was obtained as a colorless oil in the same manner as (2) of Example 1 using 11 (41 ethoxyphenyl) piperazine.
- the title compound was obtained as a colorless oil in the same manner as in Example 1 using 1- (41 trifluoromethoxyphenyl) piperazine.
- the PPAR activation action of the test compound was measured as follows.
- Receptor expression plasmid p SG 5— GAL 4—h PPAR aoryor ⁇ (LBD)
- luciferase expression plasmid p UC 8 -MH 1 00 X 4— TK_L uc
- C V-1 cells AT CC
- 3-galactosidase expression plasmid p CMX- (8- GAL) (K 1 iewer, S. A. et.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/920,940 US20090203908A1 (en) | 2005-05-25 | 2006-05-24 | Activator for Peroxisome Proliferator-Activated Receptor |
CA002609446A CA2609446A1 (en) | 2005-05-25 | 2006-05-24 | Activator for peroxisome proliferator-activated receptor |
EP06756770A EP1897872A1 (en) | 2005-05-25 | 2006-05-24 | Activator for peroxisome proliferator-activated receptor |
BRPI0610177A BRPI0610177A2 (pt) | 2005-05-25 | 2006-05-24 | composto ou um sal do mesmo, e, ativador para receptor ativado por proliferador de peroxissomo |
AU2006250373A AU2006250373A1 (en) | 2005-05-25 | 2006-05-24 | Activator for peroxisome proliferator-activated receptor |
JP2007517933A JPWO2006126714A1 (ja) | 2005-05-25 | 2006-05-24 | ペルオキシソーム増殖剤活性化受容体の活性化剤 |
IL187530A IL187530A0 (en) | 2005-05-25 | 2007-11-20 | Activator for peroxisome proliferator-activated receptor |
NO20076632A NO20076632L (no) | 2005-05-25 | 2007-12-21 | Aktivator for peroksisomproliferator-aktivert receptor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005152949 | 2005-05-25 | ||
JP2005-152949 | 2005-05-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006126714A1 true WO2006126714A1 (ja) | 2006-11-30 |
Family
ID=37452127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/310822 WO2006126714A1 (ja) | 2005-05-25 | 2006-05-24 | ペルオキシソーム増殖剤活性化受容体の活性化剤 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20090203908A1 (ja) |
EP (1) | EP1897872A1 (ja) |
JP (1) | JPWO2006126714A1 (ja) |
KR (1) | KR20080014075A (ja) |
CN (1) | CN101228144A (ja) |
AU (1) | AU2006250373A1 (ja) |
BR (1) | BRPI0610177A2 (ja) |
CA (1) | CA2609446A1 (ja) |
IL (1) | IL187530A0 (ja) |
NO (1) | NO20076632L (ja) |
RU (1) | RU2007148439A (ja) |
WO (1) | WO2006126714A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2356109T1 (sl) | 2008-10-10 | 2017-04-26 | Vm Discovery, Inc. | Sestavki in postopki za zdravljenje motenj zaradi uživanja alkohola, bolečine in drugih bolezni |
MX2012001932A (es) * | 2009-08-14 | 2012-03-14 | Nippon Chemiphar Co | Uso de ligandos ppar delta para el tratamiento o prevencion de enfermedades relacionadas con metabolismo/produccion de inflamacion o energia. |
US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
WO2022189856A1 (en) * | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002014291A1 (en) * | 2000-08-11 | 2002-02-21 | Nippon Chemiphar Co.,Ltd. | PPARδ ACTIVATORS |
WO2002076957A1 (fr) * | 2001-03-23 | 2002-10-03 | Nippon Chemiphar Co.,Ltd. | Activateur de recepteur active par les proliferateurs du peroxysome |
WO2003016291A1 (fr) * | 2001-08-10 | 2003-02-27 | Nippon Chemiphar Co., Ltd. | Activateur du recepteur $g(d) sensible au proliferateur de peroxysome |
JP2004520377A (ja) * | 2000-12-20 | 2004-07-08 | グラクソ グループ リミテッド | ヒトペルオキシソーム増殖因子活性化受容体の活性化剤としてのチアゾール及びオキサゾール誘導体 |
JP2004534035A (ja) * | 2001-05-11 | 2004-11-11 | グラクソ グループ リミテッド | ヒト・ペルオキシソーム増殖因子活性化受容体を活性化するフランおよびチオフェン誘導体 |
-
2006
- 2006-05-24 RU RU2007148439/04A patent/RU2007148439A/ru not_active Application Discontinuation
- 2006-05-24 CN CNA2006800266598A patent/CN101228144A/zh active Pending
- 2006-05-24 US US11/920,940 patent/US20090203908A1/en not_active Abandoned
- 2006-05-24 BR BRPI0610177A patent/BRPI0610177A2/pt not_active IP Right Cessation
- 2006-05-24 CA CA002609446A patent/CA2609446A1/en not_active Abandoned
- 2006-05-24 EP EP06756770A patent/EP1897872A1/en not_active Withdrawn
- 2006-05-24 JP JP2007517933A patent/JPWO2006126714A1/ja active Pending
- 2006-05-24 AU AU2006250373A patent/AU2006250373A1/en not_active Abandoned
- 2006-05-24 KR KR1020077030183A patent/KR20080014075A/ko not_active Application Discontinuation
- 2006-05-24 WO PCT/JP2006/310822 patent/WO2006126714A1/ja active Application Filing
-
2007
- 2007-11-20 IL IL187530A patent/IL187530A0/en unknown
- 2007-12-21 NO NO20076632A patent/NO20076632L/no not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002014291A1 (en) * | 2000-08-11 | 2002-02-21 | Nippon Chemiphar Co.,Ltd. | PPARδ ACTIVATORS |
JP2004520377A (ja) * | 2000-12-20 | 2004-07-08 | グラクソ グループ リミテッド | ヒトペルオキシソーム増殖因子活性化受容体の活性化剤としてのチアゾール及びオキサゾール誘導体 |
WO2002076957A1 (fr) * | 2001-03-23 | 2002-10-03 | Nippon Chemiphar Co.,Ltd. | Activateur de recepteur active par les proliferateurs du peroxysome |
JP2004534035A (ja) * | 2001-05-11 | 2004-11-11 | グラクソ グループ リミテッド | ヒト・ペルオキシソーム増殖因子活性化受容体を活性化するフランおよびチオフェン誘導体 |
WO2003016291A1 (fr) * | 2001-08-10 | 2003-02-27 | Nippon Chemiphar Co., Ltd. | Activateur du recepteur $g(d) sensible au proliferateur de peroxysome |
Also Published As
Publication number | Publication date |
---|---|
IL187530A0 (en) | 2008-03-20 |
BRPI0610177A2 (pt) | 2016-11-29 |
EP1897872A1 (en) | 2008-03-12 |
US20090203908A1 (en) | 2009-08-13 |
CA2609446A1 (en) | 2006-11-30 |
NO20076632L (no) | 2008-02-15 |
AU2006250373A1 (en) | 2006-11-30 |
RU2007148439A (ru) | 2009-06-27 |
CN101228144A (zh) | 2008-07-23 |
KR20080014075A (ko) | 2008-02-13 |
JPWO2006126714A1 (ja) | 2008-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4790969B2 (ja) | ペルオキシソーム増殖剤応答性受容体δの活性化剤 | |
JP5097180B2 (ja) | ペルオキシソーム増殖剤応答性受容体δの活性化剤 | |
JP4157381B2 (ja) | ペルオキシソーム増殖剤応答性受容体の活性化剤 | |
JP4276074B2 (ja) | ペルオキシソーム増殖剤応答性受容体δの活性化剤 | |
KR101507173B1 (ko) | 페록시좀 증식제 활성화 수용체 δ 의 활성화제 | |
JP5474769B2 (ja) | ペルオキシソーム増殖剤活性化受容体の活性化剤 | |
JPWO2002046176A1 (ja) | ペルオキシソーム増殖剤応答性受容体の活性化剤 | |
JP2001354671A (ja) | ペルオキシソーム増殖剤応答性受容体δの活性化剤 | |
JPWO2006059744A1 (ja) | ペルオキシソーム増殖剤活性化受容体δの活性化剤 | |
ZA200109804B (en) | Thiazole and oxazole derivatives and their pharmaceutical use. | |
US20060287304A1 (en) | Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient | |
WO2004071509A1 (ja) | オリゴデンドロサイト分化促進剤 | |
WO2006126714A1 (ja) | ペルオキシソーム増殖剤活性化受容体の活性化剤 | |
JP2009514973A (ja) | Pparモジュレーターとしての化合物および組成物 | |
JP2010504321A (ja) | インスリン抵抗性または高血糖に関連する代謝性障害の治療のためのピリジン誘導体 | |
JPWO2006090920A1 (ja) | ペルオキシソーム増殖剤活性化受容体δの活性化剤 | |
JPWO2007004733A1 (ja) | ペルオキシソーム増殖剤活性化受容体δの活性化剤 | |
RU2208610C2 (ru) | Пиперазиновые производные, способ их получения и содержащая их композиция | |
JP2007099640A (ja) | 含窒素複素環化合物、その製造方法およびそれを用いた医薬組成物 | |
WO2006041197A1 (ja) | ペルオキシソーム増殖剤活性化受容体δの活性化剤 | |
WO2002018363A2 (en) | 3-phenyl-propanoic acid derivatives as protein tyrosine phosphatase inhibitors | |
JP2007508270A (ja) | I.a.ジスリピデミアの治療におけるhppar作用物質として使用するためのチアゾール−2−カルボキシアミド誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680026659.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 187530 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/014593 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2609446 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12007502681 Country of ref document: PH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006250373 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007517933 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 564155 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006756770 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006250373 Country of ref document: AU Date of ref document: 20060524 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006250373 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077030183 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007148439 Country of ref document: RU Ref document number: 1200702793 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5976/CHENP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11920940 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0610177 Country of ref document: BR Kind code of ref document: A2 Effective date: 20071123 |